Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Angle Plc ADR (OP:ANPCY)

0.3516 +0.1029 (+41.38%)
Streaming Delayed Price Updated: 3:30 PM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Angle Plc ADR

< Previous 1 2 3 4 5 6 Next >
Angle PLC Announces Update on Submission for FDA Clearance
UPDATE ON SUBMISSION FOR FDA CLEARANCE OF THE PARSORTIX SYSTEM Response to Additional Information Request made to FDA as planned GUILDFORD, UK / ACCESSWIRE / June 4, 2021 / ANGLE plc... 
From ANGLE plc
Via AccessWire
Topics Intellectual Property
Angle PLC Announces Potential to Prevent Breast Cancer Relapse
BREAKTHROUGH RESEARCH SUPPORTS POTENTIAL USE OF PARSORTIX IN PREVENTION OF RELAPSE OF BREAST CANCER PATIENTS IN REMISSION Parsortix system successfully used to harvest cancer cells "hibernating" in the... 
From ANGLE plc
Via AccessWire
Topics Intellectual Property
Angle PLC Announces Parsortix Demonstrates Oesophageal Cancer Utility
- Parsortix system consistently harvests CTCs of high quality - Research paves the way for downstream molecular analysis to enable targeted treatment in this hard-to-treat cancer GUILDFORD, UK /... 
From ANGLE plc
Via AccessWire
Topics Death Intellectual Property
Angle PLC Announces Exercise of options and total voting rights
GUILDFORD, SURREY / ACCESSWIRE / May 19, 2021 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, announces that following the exercise of employee options, it has issued and... 
From ANGLE plc
Via AccessWire
Topics Intellectual Property
Angle PLC Announces Parsortix study uncovers targets in TNBC patients
- Parsortix system harvests intact CTCs for whole genomic sequencing identifying multiple druggable targets - Study demonstrates ctDNA and CTCs can both be analysed using the same blood sample... 
From ANGLE plc
Via AccessWire
Topics Intellectual Property
Angle PLC Announces Exercise of Options and Total Voting Rights
SURREY, UK / ACCESSWIRE / April 30, 2021 / ANGLE plc (AIM: AGL OTCQX: ANPCY), a world-leading liquid biopsy company, announces that following the exercise of employee options, it has issued and... 
From ANGLE plc
Via AccessWire
Topics Intellectual Property
Angle PLC Announces Preliminary Results
ANGLE plc ("ANGLE" or "the Company") Preliminary Results for the year ended 31 December 2020 FDA SUBSTANTIVE REVIEW PROGRESSING LAUNCH OF CLINICAL LABORATORY SERVICES FIRST LARGE-SCALE CONTRACT WITH... 
From ANGLE plc
Via AccessWire
Angle PLC- Ovarian Cancer Study Patient Enrolment Completed
PATIENT ENROLMENT COMPLETED IN OVARIAN CANCER CLINICAL VERIFICATION STUDY Headline results from the Study expected in Q4 2021 Study designed to support launch of an ovarian cancer test from ANGLE's... 
From ANGLE plc
Via AccessWire
Topics Intellectual Property
Angle PLC Announces First Large-Scale Pharma Services Contract Secured
- Contract Worth Up to US$1.2 Million With Potential for Further Contracts From the Same Customer - Parsortix System Being Utilised in Cancer Drug Trials for Liquid Biopsy Longitudinal Monitoring Which... 
From ANGLE plc
Via AccessWire
Topics Intellectual Property
Angle PLC Announces Notice of Preliminary Results and Webcast
GUILDFORD, SURREY / ACCESSWIRE / April 15, 2021 / ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, will be releasing its preliminary results for the year ended 31 December 2020... 
From ANGLE plc
Via AccessWire
Topics Intellectual Property
ANGLE's Parsortix system showcased at AACR 2021
ANGLE'S PARSORTIX SYSTEM SHOWCASED IN POSTER PRESENTATIONS AT LEADING CANCER CONFERENCE Publication of study results demonstrating the capabilities of two new assays in clinical samples at AACR 2021... 
From ANGLE plc
Via AccessWire
Topics Intellectual Property
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.